SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Jazz Pharmaceuticals entered into Amendment No. 4 to its Credit Agreement on September 23, 2026, converting existing Tranche B-2 Dollar Term Loans into new Tranche B-3 Dollar Term Loans totaling $1,895,000,000 with an extended maturity date (May 5, 2033, from May 5, 2028) and repriced interest margins (reduced by 50 basis points).
View raw filing on EDGAR →Solaris Energy Infrastructure entered into a purchase agreement on September 22, 2026 to issue $1.25 billion aggregate principal amount of 7.000% Senior Notes due 2032 in a private placement, with net proceeds of approximately $1.227 billion intended for general corporate purposes and growth capital expenditures. The Notes were priced and the offering is expected to close on October 1, 2026.
View raw filing on EDGAR →The disclosure centers on a performance stock unit award granted to CEO Daniel Heaf with a target value of $10 million, including detailed vesting conditions tied to stock price hurdles and relative shareholder return metrics. This is a compensatory arrangement for a named executive officer, fitting the exec_compensation category under Item 5.02(e). The materiality is clear given the $10 million target value and the strategic importance of CEO compensation to investors.
View raw filing on EDGAR →Range Capital Acquisition Corp. issued an unsecured promissory note in the principal amount of up to $540,000 to its sponsor on June 18, 2026, with $240,000 outstanding as of September 22, 2026. This constitutes creation of a direct financial obligation—a debt instrument with defined repayment terms (payable upon business combination or winding up) and events of default. Although the note is sponsor-related and non-interest-bearing, it remains a material debt obligation for a SPAC in its pre-combination phase.
View raw filing on EDGAR →James A. Hughes, Chief Executive Officer of Unity Bancorp and Unity Bank for over 26 years, has informed the Board of his intention to retire from executive positions effective March 31, 2027. George Boyan will succeed him as CEO effective April 1, 2027, and Hughes' retirement compensation has been modified with a SERP amendment increasing his benefit from 60% to 65%.
View raw filing on EDGAR →The exhibit discloses redemption and cancellation of US$600 million in 5.625% senior notes due 2027, representing 100% of the outstanding principal amount. While this is technically a debt retirement rather than issuance, it represents a material change in the registrant's direct financial obligations and capital structure. The redemption eliminates an entire debt instrument and is a significant financial event affecting the company's leverage profile.
View raw filing on EDGAR →Alcoa completed a $2.6 billion debt offering on September 23, 2026, consisting of $1.5 billion of 6.625% senior notes due 2034 and $1.1 billion of 6.875% senior notes due 2036, issued by wholly-owned subsidiaries and guaranteed by the parent company. The proceeds are intended to fund the cash portion of the South32 acquisition.
View raw filing on EDGAR →The press release announces the successful pricing of $425 million in senior unsecured notes with a 5-year maturity and 7.875% coupon by AIR Limited (a wholly owned subsidiary of AIR Global PLC). This is a material creation of a direct financial obligation. The issuer intends to use proceeds to repay existing term loan and revolving credit facilities and for general corporate purposes, with settlement expected October 1, 2026.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from a Special Meeting held on September 22, 2026. The filing reports final voting tallies for four proposals: amendment to Certificate of Incorporation (not approved), issuance of common stock exceeding 20% (approved), Fifth Amended and Restated 2018 Stock Incentive Plan (approved), and authorization to adjourn (approved). The approval of Proposal 2 regarding dilutive issuance of common stock and the stock incentive plan are material to investors' assessment of capital structure and equity dilution.
View raw filing on EDGAR →The Board of Directors declared a quarterly cash dividend of $0.79 per share on Class A and Class B common stock, totaling approximately $131.2 million, payable on October 15, 2026.
View raw filing on EDGAR →DIRTT Environmental Solutions completed a C$15.0 million secured term loan facility with the Business Development Bank of Canada (BDC), receiving the final C$5.0 million disbursement on September 21, 2026. The facility matures on April 30, 2032 and bears interest at BDC's floating base rate less 0.75%, strengthening the company's liquidity and providing additional financial flexibility for its transformation initiatives.
View raw filing on EDGAR →Todd M. Cello, Executive Vice President and Chief Financial Officer, has notified TransUnion of his intention to resign effective December 31, 2026, after 29 years with the company and 9 years as CFO. The departure of a long-tenured CFO is material to investors assessing the company's leadership continuity and financial oversight.
View raw filing on EDGAR →IQVIA Inc. completed issuance of $2.0 billion in 6.375% senior notes due 2034 pursuant to an Indenture dated September 23, 2026. The proceeds are being used to redeem existing notes, repay revolving credit facility debt, and pay transaction fees in a refinancing activity that materially affects the registrant's capital structure.
View raw filing on EDGAR →First Merchants Corporation entered into an underwriting agreement on September 23, 2026 to issue $100 million of 6.750% Fixed-to-Floating Rate Subordinated Notes due 2036 in a registered public offering, with proceeds intended for general corporate purposes including share repurchases. The notes are intended to qualify as Tier 2 capital for regulatory purposes.
View raw filing on EDGAR →This announcement discloses fulfillment of resumption guidance following a trading suspension, involving completion of a forensic investigation into connected transactions and loan arrangements, restatement of 2022–2023 financial statements, auditor changes, internal control review and remediation, and board/management restructuring. While the exhibit touches on financial restatement and auditor changes, the primary disclosure is the company's demonstration that it has satisfied all conditions imposed by the Hong Kong Stock Exchange for resumption of trading—a governance and regulatory compliance matter rather than a discrete financial or operational event. The material issues (investigation findings, restatement, internal control deficiencies) are disclosed as evidence of remediation and compliance, not as primary events themselves.
View raw filing on EDGAR →The disclosure centers on interim Phase 2 clinical data for ARCT-810 showing encouraging safety and biomarker results, introduction of LUNAR 2.0™ platform with 30-40 fold improvement in protein expression, and announcement of the myNEO acquisition to enhance mRNA design capabilities. While clinical progress and platform advancement are operationally significant, this is a Regulation FD disclosure (Item 7.01) of clinical and strategic updates rather than a discrete financial, governance, or legal event. The material clinical milestones and platform innovation warrant classification as operational_other rather than a more specific category.
View raw filing on EDGAR →The press release discloses a material strategic investment and share exchange between Psyence BioMed and PsyLabs: a cash investment of up to US$5 million (with US$2.4 million committed) and a reciprocal share-for-share exchange valued at approximately US$9 million on each side. These transactions materially alter ownership stakes (PsyLabs' ownership in Psyence BioMed increases from ~30.22% to ~49.89%, and Psyence BioMed's ownership in PsyLabs increases from ~29.17% to ~41.13%), constitute related-party transactions, and are subject to customary closing conditions and regulatory approvals. This represents a material acquisition/investment activity affecting control and capital structure.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on September 22, 2026. The filing reports voting outcomes for two proposals: (1) election of directors G. Cabell Williams and Henri J. Steenkamp, and (2) ratification of Ernst & Young LLP as independent auditor. The Item 5.07 designation and detailed vote tallies (votes for, against, withheld, abstentions) are unmistakable indicators of shareholder voting results, which are material to investors' understanding of corporate governance and board composition.
View raw filing on EDGAR →This press release announces the publication of three U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (PEA), expanding Clearmind's intellectual property portfolio in psychedelic-derived therapeutics. While the disclosure is operational in nature (patent publication and IP strategy), it represents a material milestone for a clinical-stage biotech company whose competitive position depends significantly on proprietary intellectual property and patent protection. The announcement explicitly notes this comes "at a significant time" as regulatory interest in these compounds grows, and the company's IP portfolio now consists of nineteen patent families with 32 granted patents—a key asset for valuation and competitive positioning.
View raw filing on EDGAR →This is a profit alert press release announcing preliminary financial guidance for the full year ending December 31, 2026. The Company discloses an expected net profit increase of no less than 100% compared to the prior year, driven by revenue growth from premium wine sales, operational efficiency gains, and vertical integration efforts. Although labeled a "profit alert" rather than final results, this forward-looking earnings guidance is material to investors and is the substance of the disclosure.
View raw filing on EDGAR →RAIN entered into a binding letter of intent on September 18, 2026, with Tensor Networks for a business combination in which Tensor Networks would become part of RAIN's publicly traded holding company. The all-stock transaction would result in Tensor Networks' equity holders owning approximately 90% of the combined company post-closing, subject to customary closing conditions including shareholder approval and Nasdaq listing approval.
View raw filing on EDGAR →The 6-K discloses results of an extraordinary general meeting held on September 21, 2026, where shareholders voted on two matters: (1) a 1-for-20 share consolidation affecting both Class A and Class B ordinary shares, and (2) adoption of a Fifth Amended Memorandum and Articles of Association conditional on the consolidation. Both resolutions passed with overwhelming majorities (360,889,111 votes for the consolidation, 6,847 against). This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the share consolidation is material to investors as it fundamentally alters share structure and par value.
View raw filing on EDGAR →This press release announces a $50 million PIPE (private investment in public equity) financing in which Maase Inc. will issue 3,878,856 Class A ordinary shares at $12.89 per share to a financial investment institution. PIPE financings are unregistered equity issuances that are dilutive to existing shareholders and represent a material capital-raising event. The disclosure explicitly identifies this as a securities purchase agreement for private equity issuance, which is the hallmark of a dilutive_issuance event.
View raw filing on EDGAR →The disclosure announces the full commercial availability of GameGolf KZN AI, the Company's next-generation golf performance platform, following a limited release period. This is a material operational milestone—the transition from limited to full commercial availability of a core product—that would affect a reasonable investor's assessment of the Company's business trajectory and revenue potential. While not fitting a specific named category, this is clearly an operational/strategic business event rather than financial, governance, legal, or existential in nature.
View raw filing on EDGAR →The filing discloses a Nasdaq minimum bid price deficiency notice (March 12, 2026) that triggered a 180-day compliance period, followed by a second 180-day extension (September 10, 2026), and ultimately resolution through regaining compliance (September 22, 2026). While the company has now cured the deficiency, the disclosure documents the delisting risk process and its resolution, which is material to investors assessing the registrant's listing status and financial condition.
View raw filing on EDGAR →Cuentas entered into a material power-as-a-service and colocation agreement with Power Upp USA for cryptocurrency mining operations, providing up to 24 megawatts of power capacity for approximately 4,200 ASIC miners with anticipated aggregate one-time charges of $5.9 million and recurring charges tied to mining revenues.
View raw filing on EDGAR →Quanome announced an approximately US$18.8 million infrastructure purchase agreement to advance its AI cloud business (XDT) through NVIDIA GPU technology. This is a material operational and strategic initiative—a significant capital commitment to build a new business line with expected Q4 2026 operational launch. While it involves a capital expenditure, it is fundamentally a strategic business development and operational milestone rather than a discrete financial obligation (debt issuance), M&A activity, or other named event type. The disclosure emphasizes execution of the company's quantum and AI systems strategy and the potential for recurring revenue, making it material to investor assessment of the company's direction and capital allocation.
View raw filing on EDGAR →Ondas Inc. completed the acquisition of three Israeli defense technology businesses—CaribouLabs Ltd., Insignito Solutions Ltd., and Ottopia Technologies Ltd.—for aggregate consideration of $56 million in cash or stock, plus up to $32 million in earnout consideration. The acquisitions are strategic to expand Ondas' autonomous defense systems platform and addressable markets, with technologies already deployed in active conflict environments.
View raw filing on EDGAR →The filing discloses that Nasdaq announced on September 17, 2026 that it will file a Form 25 with the SEC to complete the delisting of Aditxt's common stock from Nasdaq, with the delisting becoming effective ten days after the Form 25 filing. This is a definitive delisting notice under Item 3.01, not merely a delisting risk—the company's stock was already suspended on June 25, 2026, and Nasdaq has now formally announced the completion of the delisting process. This is material to any investor holding or considering the company's securities.
View raw filing on EDGAR →The disclosure announces the reconvening of an Extraordinary General Meeting of Shareholders originally scheduled for September 10, 2026, which was adjourned without a vote on the proposed business combination with WISeSat.Space Corp. The new meeting date is September 28, 2026, with an extended redemption deadline of September 24, 2026. While this is technically a notice of a rescheduled shareholder meeting rather than final vote results, it is material to investors as it concerns approval of a proposed SPAC business combination and affects redemption rights. The event is most closely aligned with shareholder_vote_results as it relates to shareholder voting on a material transaction, though the actual vote has not yet occurred.
View raw filing on EDGAR →This is a press release announcing unaudited interim financial results for the first half of 2026 (ended June 30, 2026), with accompanying condensed consolidated financial statements (income statement, balance sheet, cash flows) and non-IFRS reconciliations. The document explicitly states "Guardforce AI Reports Interim Financial Results for the First Half of 2026" and discloses revenue growth of 6.4%, operational metrics, and a net loss of $3.1 million. This is a discrete earnings announcement, not a periodic financial report filing itself, and would materially affect a reasonable investor's assessment of the company's financial performance and trajectory.
View raw filing on EDGAR →Mr. Kim Kwan Kings Wong resigned effective September 18, 2026, from his positions as non-executive director and Chairman of the Board due to health issues. While the report also discloses a transfer of controlling shareholder shares to Mr. Wong's son (Mr. Jiaxi Huang), the principal disclosed action is the departure of a named executive officer from his director and chairman roles, making exec_departure the primary classification. The resignation of the Chairman is material to investors' assessment of governance and leadership continuity.
View raw filing on EDGAR →Longeveron announced that its Phase 2b ELPIS II clinical trial did not meet its primary efficacy endpoint for laromestrocel in treating hypoplastic left heart syndrome, a material clinical development setback for a clinical-stage biotech company. Additionally, the company announced it is reviewing "all options to maximize shareholder value" and implementing "cash conservation measures," signaling potential strategic restructuring or asset sales. This is a material operational and strategic event—the failure of a pivotal trial combined with a strategic review process—but does not fit neatly into specific categories like ma_activity (no transaction announced yet) or material_impairment (no accounting charge disclosed). The operational domain is clear; the specific type is a clinical trial failure with strategic implications.
View raw filing on EDGAR →The 6-K discloses the closing of a private placement to "non-U.S. Persons" pursuant to a securities purchase agreement dated September 15, 2026, which closed on September 22, 2026. This is an unregistered sale of equity securities to foreign investors, a classic dilutive issuance. The filing references a prior 6-K disclosure on September 21, 2026 regarding entry into the SPA, and this filing confirms consummation of the transaction.
View raw filing on EDGAR →Leader's Advantage Acquisition Corp. consummated a $150 million IPO on September 21, 2026, and entered into multiple material definitive agreements including an Underwriting Agreement, Warrant Agreement, Investment Management Trust Agreement, Registration Rights Agreement, and Private Placement agreements.
View raw filing on EDGAR →The Company issued 193,125 Class A ordinary shares to underwriters ($1.93M) and 1,750,000 warrants to the Sponsor ($3.5M) pursuant to Section 4(a)(2) private placements, concurrent with the IPO.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of PodcastOne's 2026 Annual Meeting of Stockholders held on September 17, 2026, including voting outcomes on four proposals: election of seven directors, approval of an equity plan share increase to 4,000,000 shares, ratification of Macias Gini & O'Connell as independent auditor, and approval to adjourn the meeting if needed. All proposals passed with substantial majorities, and the detailed vote tallies for each director and proposal are provided as required by Item 5.07.
View raw filing on EDGAR →Myseum.AI announced its intention to apply for tokenization of its Nasdaq-listed common stock through qualified digital-asset securities platforms. This is a strategic operational initiative to modernize how shares are held and transferred using blockchain infrastructure. While the company explicitly states this "does not constitute the issuance of a new security, a change in the Company's existing capital structure or an offer to sell securities," the announcement of a material strategic program to explore blockchain-based equity representation is a significant operational development that would affect investor assessment of the company's future direction and market positioning. This does not fit neatly into existing categories (not M&A, not a dilutive issuance, not a debt matter) but represents a material operational/strategic initiative.
View raw filing on EDGAR →SCWorx received a Nasdaq delisting decision on September 17, 2026, for failure to satisfy the Publicly Held Shares Rule following a reverse stock split. Although the Company completed a private placement on September 16 to cure the deficiency and submitted a reconsideration request on September 18, it must also achieve a $1.00+ closing bid price for 10 consecutive trading days by October 5, 2026, to regain Bid Price Rule compliance, with risk that Common Stock will not resume trading by October 31, 2026.
View raw filing on EDGAR →The filing discloses an unregistered sale of 31,037,830 common shares at $1.25 per share (a premium to market under Nasdaq rules) for gross proceeds of $38.8 million to two Samoa-based entities. The transaction closed on September 22, 2026, and was exempted under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement that materially affects shareholder equity and voting power.
View raw filing on EDGAR →This Item 7.01 disclosure furnishes a transcript of a conference presentation by the incoming CEO of US Elemental discussing the proposed business combination between Constellation Acquisition Corp I, HiTech Minerals, and US Elemental Inc., along with details about the McDermitt Lithium Project. While the filing references a pending business combination (which would normally be classified as ma_activity), the Item 7.01 itself is explicitly furnished as a Regulation FD disclosure of conference remarks rather than a formal announcement of the transaction itself. The substance centers on operational and strategic details about the McDermitt project—its scale, technical differentiation, market timing, permitting status, and development roadmap—making this an operational disclosure about a material project milestone and strategic positioning ahead of the business combination closing.
View raw filing on EDGAR →LiveOne held its 2026 Annual Meeting of Stockholders on September 17, 2026, with voting results on four proposals: election of seven directors, approval of the 2026 Equity Incentive Plan, ratification of Macias Gini & O'Connell as independent auditor, and adjournment authority.
View raw filing on EDGAR →Greenland Mines entered into a securities purchase agreement to sell 1,765,420 shares of common stock and pre-funded warrants exercisable for 1,434,580 additional shares in a registered direct offering, raising approximately $38.4 million in net proceeds. This is a material dilutive equity issuance to institutional investors at $12.00 per share, representing a substantial capital raise that would significantly dilute existing shareholders and materially affect the registrant's capitalization.
View raw filing on EDGAR →The disclosure announces the expiration and delisting of the Company's publicly traded warrants (NTRBW) from Nasdaq effective September 30, 2026. While the warrant expiration is automatic under the Warrant Agreement and does not affect the common stock listing, the removal of a security from Nasdaq listing is a material event affecting warrant holders' ability to trade and exercise their securities. This constitutes a delisting event under Item 3.01 principles, though the common stock itself remains listed.
View raw filing on EDGAR →Lion Group announces progress on a proposed restructuring of Skyfame Realty (Holdings) Limited, in which Lion Wealth Management Limited (a wholly-owned subsidiary) entered into an exclusivity agreement on 10 April 2026. The press release notes Skyfame's submission of a resumption proposal to the Hong Kong Stock Exchange and the High Court's grant of leave to convene a scheme creditors meeting. This is a material strategic transaction involving a subsidiary's involvement in a restructuring of another entity, but it does not fit the specific M&A categories (no completed acquisition, merger, or change of control is disclosed here—only ongoing restructuring negotiations). The disclosure is operational and strategic in nature, warranting classification as operational_other rather than ma_activity, since the restructuring remains proposed and contingent with no assurance of completion.
View raw filing on EDGAR →The filing discloses the appointment of Mr. Letao Zhao as an independent director and member of three board committees, including chairperson of the Compensation Committee, effective September 18, 2026. While the filing also mentions the resignation of Mr. Mike Yao Zhou on the same date, the principal disclosed action is the appointment of a new director to fill the vacancy. The appointment of an independent director to multiple committees is material to governance and investor assessment.
View raw filing on EDGAR →This news release announces a material clinical trial milestone: achievement of the Phase III MAVERIC enrollment target (110 patients) ahead of schedule, coupled with a planned expansion to 150 patients based on a blinded review showing fewer-than-expected recurrences. The disclosure includes revised topline results guidance (mid-2027 vs. Q1 2027) and cash runway extension to Q1 2028. While this is an operational/clinical development event rather than a discrete financial event (earnings, debt, M&A, or litigation), it materially affects investor assessment of the registrant's lead program progress and capital adequacy for a late-stage biotech company.
View raw filing on EDGAR →This news release announces amendments to the Company's Articles of Incorporation to be voted on at the annual general and special meeting, including changes to quorum requirements (increasing shareholder quorum from 5% to 25%), elimination of alternate directors, and modifications to advance notice provisions for director nominations. The postponement of the meeting from September 25 to October 2, 2026 is also disclosed. These are governance-related matters that would affect shareholder voting rights and board operations, making them material to investors assessing corporate governance structure, though they do not fit the specific categories of exec_appointment, exec_departure, or shareholder_vote_results (which would apply to results of a vote, not the proposal itself).
View raw filing on EDGAR →Aurora Cannabis has disclosed a hostile takeover bid by Curaleaf Holdings, Inc., and filed an application with the Alberta Securities Commission challenging deficiencies in Curaleaf's bid circular. The disclosure addresses a material acquisition activity (the hostile bid itself) and Aurora's defensive response, including the Board's unanimous recommendation to reject the bid and the potential triggering of Aurora's Shareholder Rights Plan. This is a change-of-control event that would materially affect investor assessment of the registrant.
View raw filing on EDGAR →The exhibit announces the appointment of Rafael Siqueira as Chief Technology Officer (CTO) of Agi Inc, a named executive officer role. The disclosure emphasizes his 30 years of technology experience and 16+ years as CTO, his mandate to lead the Technology division and accelerate AI strategy, and notes that his appointment as a statutory officer of Banco Agibank is subject to Central Bank of Brazil approval. This is a material executive appointment that would affect investor assessment of the company's technology leadership and strategic direction.
View raw filing on EDGAR →